BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37807669)

  • 1. Discovery of NSD2-Degraders from Novel and Selective DEL Hits.
    LegaardAndersson J; Christensen J; Kleine-Kohlbrecher D; Vacher Comet I; Fullerton Støier J; Antoku Y; Poljak V; Moretti L; Dolberg J; Jacso T; Jensby Nielsen S; Nørregaard-Madsen M; Franch T; Helin K; Cloos PAC
    Chembiochem; 2023 Dec; 24(24):e202300515. PubMed ID: 37807669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.
    Sankaran SM; Wilkinson AW; Elias JE; Gozani O
    J Biol Chem; 2016 Apr; 291(16):8465-74. PubMed ID: 26912663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization.
    Dilworth D; Hanley RP; Ferreira de Freitas R; Allali-Hassani A; Zhou M; Mehta N; Marunde MR; Ackloo S; Carvalho Machado RA; Khalili Yazdi A; Owens DDG; Vu V; Nie DY; Alqazzaz M; Marcon E; Li F; Chau I; Bolotokova A; Qin S; Lei M; Liu Y; Szewczyk MM; Dong A; Kazemzadeh S; Abramyan T; Popova IK; Hall NW; Meiners MJ; Cheek MA; Gibson E; Kireev D; Greenblatt JF; Keogh MC; Min J; Brown PJ; Vedadi M; Arrowsmith CH; Barsyte-Lovejoy D; James LI; Schapira M
    Nat Chem Biol; 2022 Jan; 18(1):56-63. PubMed ID: 34782742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
    Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
    J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors.
    Li N; Yang H; Liu K; Zhou L; Huang Y; Cao D; Li Y; Sun Y; Yu A; Du Z; Yu F; Zhang Y; Wang B; Geng M; Li J; Xiong B; Xu S; Huang X; Liu T
    J Med Chem; 2022 Jul; 65(13):9459-9477. PubMed ID: 35704853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
    Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
    J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of LLC0424 as a Potent and Selective
    Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
    Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
    Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer.
    Zhao LH; Li Q; Huang ZJ; Sun MX; Lu JJ; Zhang XH; Li G; Wu F
    Cell Death Dis; 2021 Oct; 12(11):974. PubMed ID: 34671018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2.
    Sato K; Kumar A; Hamada K; Okada C; Oguni A; Machiyama A; Sakuraba S; Nishizawa T; Nureki O; Kono H; Ogata K; Sengoku T
    Nat Commun; 2021 Nov; 12(1):6605. PubMed ID: 34782608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
    Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z
    Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.
    Zheng Y; Fornelli L; Compton PD; Sharma S; Canterbury J; Mullen C; Zabrouskov V; Fellers RT; Thomas PM; Licht JD; Senko MW; Kelleher NL
    Mol Cell Proteomics; 2016 Mar; 15(3):776-90. PubMed ID: 26272979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36.
    Poulin MB; Schneck JL; Matico RE; McDevitt PJ; Huddleston MJ; Hou W; Johnson NW; Thrall SH; Meek TD; Schramm VL
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1197-201. PubMed ID: 26787850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.
    Hanley RP; Nie DY; Tabor JR; Li F; Sobh A; Xu C; Barker NK; Dilworth D; Hajian T; Gibson E; Szewczyk MM; Brown PJ; Barsyte-Lovejoy D; Herring LE; Wang GG; Licht JD; Vedadi M; Arrowsmith CH; James LI
    J Am Chem Soc; 2023 Apr; 145(14):8176-8188. PubMed ID: 36976643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.
    Ferreira de Freitas R; Liu Y; Szewczyk MM; Mehta N; Li F; McLeod D; Zepeda-Velázquez C; Dilworth D; Hanley RP; Gibson E; Brown PJ; Al-Awar R; James LI; Arrowsmith CH; Barsyte-Lovejoy D; Min J; Vedadi M; Schapira M; Allali-Hassani A
    J Med Chem; 2021 Feb; 64(3):1584-1592. PubMed ID: 33522809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
    Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
    Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.
    Zhang L; Zha X
    Eur J Med Chem; 2023 Mar; 250():115232. PubMed ID: 36863225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
    Morishita M; Mevius D; di Luccio E
    BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H3K36me2 methyltransferase NSD2 orchestrates epigenetic reprogramming during spermatogenesis.
    Li Z; Zhang X; Xie S; Liu X; Fei C; Huang X; Tang Y; Zhou LQ
    Nucleic Acids Res; 2022 Jul; 50(12):6786-6800. PubMed ID: 35736136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
    García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
    Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.